- Conditions
- Ovarian Cancer
- Interventions
- Monoclonal antibody hu3S193
- Biological
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2809–2832
of 8,384
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Renal Cell Carcinoma
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Sunitinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 915 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 28
- States / cities
- Tucson, Arizona • Orange, California • San Francisco, California + 22 more
- Conditions
- Lymphoma, B-Cell
- Interventions
- Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Food Allergy
- Interventions
- Omalizumab
- Biological
- Lead sponsor
- AAADRS Clinical Research Center
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Coral Gables, Florida
- Conditions
- Demyelinating Diseases, Paraproteinemias
- Interventions
- intravenous immunoglobulin (IVIg)
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1990 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic or Unresectable Melanoma
- Interventions
- Nivolumab, Talazoparib
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Metastatic Cancer
- Interventions
- Keytruda Injectable Product, Yervoy Injectable Product, Cytoxan, Cryosurgical freezing (cryosurgery), GM-CSF Injectable
- Drug · Procedure
- Lead sponsor
- Rampart Health, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Michigan
- Conditions
- Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma
- Interventions
- Irinotecan, Ramucirumab, Blood for angiome profiling, Blood for cfDNA
- Drug · Genetic
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 4
- States / cities
- Miami, Florida • Tampa, Florida • St Louis, Missouri + 1 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control
- Drug · Procedure · Other
- Lead sponsor
- Jeffrey Gelfand
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Head and Neck Cancer, Carcinoma, Squamous
- Interventions
- Oxaliplatin, Docetaxel, Cetuximab
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Rheumatoid Arthritis
- Interventions
- Adalimumab, Baricitinib, Methotrexate, Adalimumab Placebo, Baricitinib Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 45
- States / cities
- Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 39 more
- Conditions
- Cancer
- Interventions
- JTX-2011, Nivolumab, Ipilimumab, Pembrolizumab
- Drug
- Lead sponsor
- Jounce Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 16
- States / cities
- Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 11 more
- Conditions
- Breast Cancer
- Interventions
- pertuzumab, trastuzumab
- Biological
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, fludarabine phosphate, Melphalan, mycophenolate mofetil, tacrolimus, umbilical cord blood transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Heart Failure
- Interventions
- O2 consumption max bike test
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Graft-vs.-Host Disease
- Interventions
- Alemtuzumab (Campath)
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hairy Cell Leukemia
- Interventions
- Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Spinal Cord Injury, Vitamin D Deficiency
- Interventions
- Vitamin D3
- Drug
- Lead sponsor
- James J. Peters Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Juvenile Myelomonocytic Leukemia
- Interventions
- tipifarnib, isotretinoin, fludarabine phosphate, cytarabine, radiation therapy, cyclophosphamide, anti-thymocyte globulin, allogeneic bone marrow transplantation, double-unit umbilical cord blood transplantation, umbilical cord blood transplantation, laboratory biomarker analysis
- Drug · Radiation · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 18 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Age-Related Macular Degeneration
- Interventions
- 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more
- Conditions
- Adult Male Hypogonadism
- Interventions
- Testosterone gel (FE 999303)
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 17
- States / cities
- Huntsville, Alabama • Newport Beach, California • San Diego, California + 14 more
- Conditions
- Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
- Interventions
- cyclophosphamide, paclitaxel, trastuzumab, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 20 Years and older · Female only
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Grand Island, Nebraska • Omaha, Nebraska
- Conditions
- Colorectal Adenocarcinoma, CpG Island Methylator Phenotype, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Guadecitabine, Nivolumab
- Drug · Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Newport Beach, California
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
- Interventions
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Genetic · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 671 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 89
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more